$1.51 Billion is the total value of Frazier Life Sciences Management, L.P.'s 52 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 44.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| KRYS | Sell | KRYSTAL BIOTECH INC | $114,661,360 | -1.4% | 988,460 | -0.2% | 7.62% | +9.7% |
| ACAD | Sell | ACADIA PHARMACEUTICALS INC | $13,147,893 | -36.0% | 630,897 | -26.4% | 0.87% | -28.8% |
| SNDX | Sell | SYNDAX PHARMACEUTICALS INC | $8,712,000 | -88.8% | 600,000 | -83.8% | 0.58% | -87.5% |
| GRTS | Sell | GRITSTONE BIO INC | $2,461,110 | -47.4% | 1,430,878 | -40.4% | 0.16% | -41.8% |
| PASG | Sell | PASSAGE BIO INC | $1,156,908 | -33.6% | 1,758,219 | -5.0% | 0.08% | -26.0% |
| IMVT | Exit | IMMUNOVANT INC | $0 | – | -300,000 | -100.0% | -0.34% | – |
| RETA | Exit | REATA PHARMACEUTICALS INCcl a | $0 | – | -100,430 | -100.0% | -0.61% | – |
| MORF | Exit | MORPHIC HLDG INC | $0 | – | -265,511 | -100.0% | -0.91% | – |
| KDNY | Exit | CHINOOK THERAPEUTICS INC | $0 | – | -4,345,559 | -100.0% | -9.97% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ARCUTIS BIOTHERAPEUTICS INC | 7 | Q3 2023 | 17.0% |
| MIRUM PHARMACEUTICALS INC | 7 | Q3 2023 | 13.6% |
| PHATHOM PHARMACEUTICALS INC | 7 | Q3 2023 | 8.6% |
| KRYSTAL BIOTECH INC | 7 | Q3 2023 | 7.6% |
| SYNDAX PHARMACEUTICALS INC | 7 | Q3 2023 | 6.3% |
| VAXCYTE INC | 7 | Q3 2023 | 4.8% |
| CRINETICS PHARMACEUTICALS IN | 7 | Q3 2023 | 3.1% |
| ALPINE IMMUNE SCIENCES INC | 7 | Q3 2023 | 3.2% |
| TARSUS PHARMACEUTICALS INC | 7 | Q3 2023 | 2.5% |
| KALVISTA PHARMACEUTICALS INC | 7 | Q3 2023 | 2.1% |
View Frazier Life Sciences Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR/A | 2023-02-07 |
| 13F-HR | 2023-02-03 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-10 |
| 13F-HR | 2022-05-16 |
View Frazier Life Sciences Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.